Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Condition: Tuberculosis Interventions: Biological: GamTBvac; Biological: Placebo Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Epidemiology | Microbiology | Research | Russia Health | Study | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines